These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 31672704)

  • 1. Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas.
    Murga-Zamalloa CA; Brown NA; Wilcox RA
    J Clin Pathol; 2020 Apr; 73(4):197-203. PubMed ID: 31672704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
    Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
    El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
    Al-Badran SS; Grant L; Campo MV; Inthagard J; Pennel K; Quinn J; Konanahalli P; Hayman L; Horgan PG; McMillan DC; Roxburgh CS; Roseweir A; Park JH; Edwards J
    J Pathol Clin Res; 2021 Mar; 7(2):121-134. PubMed ID: 33338327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
    Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
    ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute
    Herrmann M; Schulte S; Wildner NH; Wittner M; Brehm TT; Ramharter M; Woost R; Lohse AW; Jacobs T; Schulze Zur Wiesch J
    Front Immunol; 2020; 11():1870. PubMed ID: 32983106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL.
    Liao Z; Lv X; Liu S; He Z; Chen S; Wang L; Li W; Li Y
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e252-e258. PubMed ID: 29368793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma.
    Yoshida T; Nakamoto T; Atsumi N; Ohe C; Sano T; Yasukochi Y; Tsuta K; Kinoshita H
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39043605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The expression and prognostic value of PD-1, TIM-3, LAG-3 and BTLA in extranodal NK/T cell lymphoma].
    Nie L; Liu XY; Ma RJ; Yuan XL; Jiang L; Yang J; Hu AX; Li Z; Zhu ZM
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):598-602. PubMed ID: 34455749
    [No Abstract]   [Full Text] [Related]  

  • 11. Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype.
    Shokrgozar N; Karimi M; Golmoghaddam H; Rezaei N; Moayed V; Sharifzadeh S; Arandi N
    Ann Hematol; 2021 Oct; 100(10):2463-2469. PubMed ID: 34324022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
    Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
    Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival.
    Tu L; Guan R; Yang H; Zhou Y; Hong W; Ma L; Zhao G; Yu M
    Int J Cancer; 2020 Jul; 147(2):423-439. PubMed ID: 31721169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.
    Zelba H; Bedke J; Hennenlotter J; Mostböck S; Zettl M; Zichner T; Chandran A; Stenzl A; Rammensee HG; Gouttefangeas C
    Cancer Immunol Res; 2019 Nov; 7(11):1891-1899. PubMed ID: 31484656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
    Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
    J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.
    Kamal AM; Wasfey EF; Elghamry WR; Sabry OM; Elghobary HA; Radwan SM
    Clin Biochem; 2021 Oct; 96():13-18. PubMed ID: 34217699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
    Dempke WCM; Fenchel K; Uciechowski P; Dale SP
    Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis.
    Lavon I; Heli C; Brill L; Charbit H; Vaknin-Dembinsky A
    Front Immunol; 2019; 10():835. PubMed ID: 31134049
    [No Abstract]   [Full Text] [Related]  

  • 19. Functional exhaustion of CD4
    Ozkazanc D; Yoyen-Ermis D; Tavukcuoglu E; Buyukasik Y; Esendagli G
    Immunology; 2016 Dec; 149(4):460-471. PubMed ID: 27565576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
    Anderson AC; Joller N; Kuchroo VK
    Immunity; 2016 May; 44(5):989-1004. PubMed ID: 27192565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.